Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021 WOBURN, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today...

Biofrontera dismisses case against DUSA Pharmaceuticals, Inc. in California state court Leverkusen, Germany, May 13, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or “Biofrontera”), an international biopharmaceutical company, today...

Biofrontera announces preliminary unaudited sales revenue and updates consolidated net income guidance for the full year 2018 Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), an international biopharmaceutical...

Ruling by the U.S. District Court of Massachussetts Leverkusen, Germany, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today comments on a...